Similarly, in a study performed in 122 patients with advanced HCC treated with sorafenib, Miyahara et al. confirmed that an elevated expression of Ang-2 was associated with a shorter PFS (HR 1.84) and OS (HR 1.95) [51]. This evidence concerns the gene ANGPT2 and hepatocellular carcinoma.